The UK and US have concluded a important bilateral deal that will keep zero tariffs on British medicine exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to raise expenditure on pharmaceuticals through the public health system. This commitment secures that import taxes on these key products will stay at zero for a period of 36 months.
This development is in response to previous warnings to significantly raise import taxes on patented drug products, with increases mentioned up to 100%.
"This arrangement with the UK strengthens the global environment for new treatments and brings long-overdue fairness to American-British medicine commerce," a statement declared.
Commercial Impact
Medicines constitute one of the Britain's largest exports to the America, which is clearly the biggest market for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to September, the UK exported drugs totaling over eleven billion pounds to the US. This amount represented a significant portion of total UK exports in that period.
"This guarantee protects employment, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Key British Pledges
The agreement entails several key changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a target to raise total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be restricted at fifteen percent. In the past, rebates exceeded 20%.
Industry Background
The deal follows a protracted row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
This friction were intensified by claims that US consumers were paying significantly more for the identical medicines than consumers in the UK and Europe.
Recently, several significant drug company projects in the UK have been delayed or cancelled, while substantial investments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had decreased as a percentage of its resources over the past decade.
